Bethanecol

Overview

Bethanechol (Urecholine®) is a direct-acting cholinergic (parasympathomimetic) agent used in dogs and cats primarily to stimulate urinary bladder contractility. It is most commonly prescribed for detrusor atony and certain forms of functional urinary retention.

In addition to its effects on the urinary bladder, bethanechol can act as a gastrointestinal prokinetic by increasing smooth muscle tone and peristalsis. However, in small animal practice, other prokinetic agents are often better tolerated for routine GI indications.

Mechanism of Action (MOA): Bethanechol directly stimulates muscarinic cholinergic receptors with minimal nicotinic activity at recommended doses. It increases detrusor muscle tone, enhances esophageal and intestinal motility, increases gastric and pancreatic secretions, and reduces bladder capacity. The drug is relatively resistant to cholinesterase degradation, resulting in a longer duration of action compared with acetylcholine.

Indications

Bethanechol is used in dogs and cats to stimulate smooth muscle contraction in the urinary and gastrointestinal tracts. It is most effective when functional atony is present rather than mechanical obstruction.

• Detrusor atony (urinary retention): Used to stimulate urinary bladder contractions in cases of acute or partial detrusor atony, particularly following bladder overdistension or partial neurogenic dysfunction.
• Adjunctive therapy for urinary outflow dysfunction: May be combined with agents that reduce urethral resistance (e.g., alpha-adrenergic antagonists or skeletal muscle relaxants) when increased urethral tone is present and mechanical obstruction has been ruled out.
• Esophageal hypomotility: May be used as an esophageal prokinetic to enhance peristalsis and lower esophageal sphincter tone.
• General GI hypomotility: Can be used as a gastrointestinal prokinetic agent; however, alternative prokinetics are often preferred due to better tolerability.

Dosage (Reference)

Dog

In dogs, bethanechol is administered orally for stimulation of urinary bladder contraction. Dosing is based on a fixed amount per dog rather than mg/kg, and gradual dose titration is recommended to minimize cholinergic adverse effects.

Cat

In cats, bethanechol is administered orally for treatment of detrusor atony. As in dogs, gradual dose titration is recommended to minimize adverse cholinergic effects.

Warnings & Precautions

Bethanechol is a direct-acting muscarinic agonist that increases smooth muscle tone in the urinary and gastrointestinal tracts. Careful patient selection is essential, as inappropriate use may worsen obstruction or precipitate severe cholinergic effects.

• Urinary outflow obstruction: Contraindicated in patients with mechanical urinary obstruction. Stimulation of detrusor contraction against a closed outlet may cause bladder rupture or retrograde urine reflux.
• Bladder wall integrity: Do not use when bladder integrity is compromised (e.g., recent bladder surgery or suspected rupture).
• Gastrointestinal obstruction or inflammation: Contraindicated in GI obstruction, peritonitis, active peptic ulcer disease, or recent GI resection with anastomosis.
• Bronchoconstrictive disease: Use is contraindicated in patients with asthma or other bronchoconstrictive disorders due to risk of bronchospasm and increased bronchial secretions.
• Cardiovascular instability: Avoid use in severe bradycardia, hypotension, vagotonia, or vasomotor instability.
• Hyperthyroidism: Contraindicated due to increased risk of arrhythmias and exaggerated cholinergic responses.
• Epilepsy: Use with caution, as cholinergic stimulation may lower seizure threshold.
• Urethral resistance: When increased urethral tone is present (functional obstruction), bethanechol should only be used with agents that reduce outflow resistance; it is not effective for mechanical obstruction.
• Parenteral administration: IV or IM use is not recommended except in emergency situations. Severe cholinergic reactions may occur; atropine should be readily available if injectable administration is performed.

Drug Interactions

Clinically relevant interactions with bethanechol are primarily related to additive or antagonistic cholinergic effects, as well as potential cardiovascular or bronchial complications. Careful monitoring is recommended when combining bethanechol with the following agents.

• Anticholinergic drugs (e.g., atropine, glycopyrrolate, propantheline): May antagonize the effects of bethanechol and reduce its therapeutic efficacy.
• Other cholinergic drugs (e.g., neostigmine, physostigmine, pyridostigmine): Concurrent use may result in excessive cholinergic stimulation and should generally be avoided.
• Beta-adrenergic antagonists: May increase the risk of arrhythmias and bronchospasm when used concurrently.
• Ganglionic blocking agents (e.g., mecamylamine, trimethaphan): May produce severe gastrointestinal and hypotensive effects when combined.
• Quinidine or procainamide: May antagonize the effects of bethanechol.

Side Effects & Overdose

Side Effects

Adverse effects of bethanechol are related to excessive muscarinic (cholinergic) stimulation. When administered orally at recommended doses in dogs and cats, effects are typically mild and dose-dependent.

• Gastrointestinal signs: Vomiting, diarrhea, abdominal cramping, and anorexia are the most commonly reported effects.
• Hypersalivation: Increased drooling due to cholinergic stimulation of salivary glands.
• Increased urination: Resulting from detrusor muscle stimulation.
• Miosis: Pupillary constriction may occur with systemic cholinergic stimulation.
• Respiratory effects (rare at oral doses): Bronchoconstriction or increased bronchial secretions, typically associated with high doses or parenteral administration.
• Cardiovascular effects (rare at oral doses): Tachycardia, arrhythmias, or hypotension are generally associated with overdose or injectable administration.
• Laboratory changes: May increase pancreatic enzyme activity (amylase, lipase) and cause mild elevations in bilirubin or AST due to sphincter of Oddi contraction.

Overdose

Clinical signs of overdose are cholinergic in nature and may range from exaggerated muscarinic effects to life-threatening cholinergic crisis, particularly if administered IM or IV.

• Muscarinic signs: Salivation, lacrimation, urination, defecation, vomiting, diarrhea (SLUDGE-type signs).
• Severe cholinergic crisis (IM/IV overdose): Bronchospasm, circulatory collapse, bloody diarrhea, shock, or cardiac arrest may occur.
• Management: Atropine is the treatment of choice for bethanechol toxicity.
• Adjunctive therapy: Epinephrine may be used for treatment of bronchospasm if clinically indicated.

Key Notes

Practical clinical considerations to optimize safe and effective use of bethanechol in dogs and cats:

• Muscarinic selectivity: Bethanechol primarily stimulates muscarinic receptors with negligible nicotinic activity at recommended doses.
• Cholinesterase resistance: More resistant to hydrolysis than acetylcholine, resulting in a longer duration of action.
• Route-dependent onset: Oral onset is typically within 30–90 minutes, whereas SC administration produces effects within 5–15 minutes with peak response around 30 minutes.
• Duration of effect: Oral administration may last up to 6 hours at higher doses; SC effects generally persist for approximately 2 hours.
• No CNS penetration: Does not cross the blood–brain barrier at recommended doses.
• Ceiling effect: Higher doses may produce reduced response due to receptor desensitization and intracellular calcium depletion.
• Administration with food: Giving with food may help reduce nausea and vomiting.